Brief: Natera Says Signatera Receives Regulatory Approval In Japan For Colorectal Cancer
24/06/2026 08:01
BRIEF-Natera Says Signatera Receives Regulatory Approval In Japan For Colorectal Cancer June 24 (Reuters) - Natera Inc NTRA.O:
SIGNATERA™ RECEIVES REGULATORY APPROVAL IN JAPAN FOR COLORECTAL CANCER
NATERA INC - NATERA EXPECTS TO COMMERCIALLY LAUNCH SIGNATERA FOR CRC IN JAPAN BY END OF 2026
Source text: ID:nBw25Ymmca
Further company coverage: NTRA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Natera
See all newsBrief: FDA Grants Breakthrough Device Designation For Natera’S Multi-Cancer Early Detection Assay
Brief: Alliance Foundation Trials And Natera Announce Aft-70 Navigate A Global, Randomized, Phase Iii Trial Evaluating Genentech’S Oral Selective Estrogen Receptor Degrader With Signatera Mrd-Guided Cdk4/6 Inhibitor Therapy In Breast Cancer
US RESEARCH ROUNDUP-Chevron, Exxon Mobil, GoDaddy
Brief: Natera Says Signatera Commercial Launch In Japan Expected In 1H 2027
Brief: Natera To Support New Clinical Trial Assessing Ctdna Dynamics With Latitud In Advanced Skin Cancers